STRESAM STREZAM (Etifoxine) 60 capsules


SpecificationsActive substances EthifoxinCountry of ProductionfranceProductionbiocodex The form of the capsule release is 50 mg in a pack of 60 pcs.


Active substances Ethifoxin
Country of Productionfrance
The form of the capsule release is 50 mg in a pack of 60 pcs.
Keep away from children
Dosage form
smooth shiny gelatin capsules No. 2 with a white body and a blue lid. The contents are white or white powder with a slight yellowish tinge of color.
1 capsule contains:
Ethifoxin hydrochloride 50 mg
Lactose monohydrate 119 mg
Talc 15 mg
Microcrystalline cellulose 10 mg
Colloidal anhydrous silicon dioxide 3 mg
Magnesium stearate 3 mg
The composition of the capsule shell:
titanium dioxide
General Description
anxiolytic agent (tranquilizer)
Special conditions
If skin or allergic reactions occur, as well as complications from the liver, the drug
should be discontinued.
If you miss taking the drug, you should not double the dose at the next intake.
Due to the risk of drowsiness, it is necessary to avoid driving vehicles and
activities that require increased attention, for example, controlling various mechanisms, during treatment.
Drug interaction
potentiates the effect of drugs that depress the central nervous system, such as opioid analgesics, barbiturates, sleeping pills, antihistamines, neuroleptics, etc. It also increases the effect of alcohol.
Ethifoxin hydrochloride belongs to the benzoxazine derivatives.
As an anxiolytic agent, ethi-foxin has an autonomous regulating effect. In vitro and in vivo studies in rats and mice, it was shown that the anxiolytic activity of ethifoxin is due to the dual mechanism of its action (direct and indirect) on GABA-A receptors, which improves GABA-ergic impulse transmission.
When directly acting on the GABA-A receptor by allosteric modulation, etifoxin binds mainly to the subunits (32 or RZ of the receptor; studies have shown that etifoxin binds to the GABA-A receptor at sites other than the binding site of benzodiazepines. The indirect effect is provided by increasing the synthesis of neurosteroids (by activating the mitochondrial translocator protein,), such as allopregna-nolone, which is also a positive allosteric modulator of the G AMK-A receptor.
it is rapidly absorbed from the gastrointestinal tract, quickly metabolized in the liver to the formation of several metabolites. One of the metabolites (diethylethyphoxine) is active, and its half-life is about 20 hours. Penetrates through the placental barrier.
The time to reach the maximum concentration in the blood is 2-3 hours, the half-life is about 6 hours.
It is excreted mainly in the urine in the form of metabolites, as well as in unchanged form in small quantities.
It is also excreted with bile.
Treatment of psychosomatic manifestations of anxiety.
Hypersensitivity to the active ingredient or other component of the drug,
shock, myasthenia gravis, severe disorders of the liver and/or kidneys.
Due to the presence of lactose in the composition of the drug, the drug should not be used for galactosemia, glucose and galactose malabsorption syndrome, as well as in the case of lactase deficiency. It is not recommended to use it under the age of 18 years.
symptoms: lethargy, excessive drowsiness. Treatment: gastric lavage with a large amount of water, symptomatic treatment. There is no specific antidote.
Side effects
The following are the adverse events (NS) that were observed when taking this drug, according to the classification by system-organ classes and frequency of occurrence (“rare”:>1/10 000 and < 1/1000, "very rare": <1/10 000) in descending order of frequency. Disorders of the nervous system are rare: slight drowsiness that appears in the first days of admission and usually disappears independently during treatment. Disorders of the skin and subcutaneous tissue Rarely, skin reactions: maculopapular rashes, erythema multiforme, itching, swelling of the face. Very rare: allergic reactions: urticaria, Quincke's edema. The frequency has not been established: anaphylactic shock, drug-induced hypersensitivity syndrome with eosinophilia, Stevens-Johnson syndrome, leukocytoclastic vasculitis. Violations from the liver and biliary tract, The frequency is not established: hepatitis, cytolytic hepatitis. Disorders of the genitals and breast The frequency is not established: metrorrhagia in women taking oral contraceptives. Disorders of the gastrointestinal tract The frequency is not established: lymphocytic colitis.